Cyclerion Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.9M-5.0% YoYTTM through 30 Jun 2026
Net Income -$6.7MTTM through 30 Jun 2026
Free Cash Flow -$4.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -322.5% |
| Operating Margin | -240.1% |
| Net Margin | -353.0% |
Returns
-38.8%ROE
-35.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.16x
Net Debt-$3.2Mnet cash position
Cash & Equivalents$1.4M
Quality Metrics
Altman Z-Score-53.66
Piotroski F-Score3 / 9
FCF Margin-248.2%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $2.1M
Diluted EPS-$1.66TTMFY2025: $-1.11
Dividend
No dividend
Capital Allocation
R&D Spend$1.6M
Capex Intensity13.9%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.